Year-end report 2019 Bactiguard Holding AB
A strong development in fourth quarter earnings, combined with the licensing deal with Zimmer Biomet led to the highest full-year result in Bactiguard's history. The financial effects of both increased BIP sales and new license revenues clearly show that our growth strategy works.Fourth quarter (October-December 2019) · Revenues amounted to SEK 61.6 (42.1) million, an increase of 46% mainly driven by higher BIP sales but also higher license revenues from BD. · BIP sales amounted to SEK 25.3 (14.4) million. The increase of 75% is essentially a result of positive development in China